Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

Open access
van Poelgeest, Mariëtte I.E., Welters, Marij J.P., Vermeij, Renee, Stynenbosch, Linda F.M., Loof, Nikki M., Berends-van der Meer, Dorien M.A., Löwik, Margriet J.G., Hamming, Ineke L.E., van Esch, Edith M.G., Hellebrekers, Bart W.J., van Beurden, Marc, Schreuder, Henk W., Kagie, Marjolein J., Trimbos, J. Baptist M.Z., Fathers, Lorraine M., Daemen, Toos, Hollema, Harry, Valentijn, A. Rob P.M., Oostendorp, Jaap, Oude Elberink, J. Hanneke N.G., Fleuren, Gertjan J., Bosse, Tjalling, Kenter, Gemma G., Stijnen, Theo, Nijman, Hans W., Melief, Cornelis J.M., van der Burg, Sjoerd H. · 2016 · Clinical Cancer Research

Abstract

Purpose: Therapeutic vaccination with human papillomavirus type 16 (HPV16) E6 and E7 synthetic long peptides (SLP) is effective against HPV16-induced high-grade vulvar and vaginal intraepithelial neoplasia (VIN/VaIN). However, clinical nonresponders displayed weak CD8+ T-cell reactivity. Here, we studied if imiquimod applied at the vaccine site could improve CD8+ T-cell reactivity, clinical efficacy, and safety of HPV16-SLP (ISA101). Experimental Design: A multicenter open-label, randomized controlled trial was conducted in patients with HPV16+ high-grade VIN/VaIN. Patients received ISA101 vaccination with or without application of 5% imiquimod at the vaccine site. The primary objective was the induction of a directly ex vivo detectable HPV16-specific CD8+ T-cell response. The secondary objectives were clinical responses (lesion size, histology, and virology) and their relation with the strength of vaccination-induced immune responses. Results: Forty-three patients were assigned to either ISA101 with imiquimod (n = 21) or ISA101 only (n = 22). Imiquimod did not improve the outcomes of vaccination. However, vaccine-induced clinical responses were observed in 18 of 34 (53%; 95% CI, 35.1–70.2) patients at 3 months and in 15 of 29 (52%; 95% CI, 32.5–70.6) patients, 8 of whom displayed a complete histologic response, at 12 months after the last vaccination. All patients displayed vaccine-induced T-cell responses, which were significantly stronger in patients with complete responses. Importantly, viral clearance occurred in all but one of the patients with complete histologic clearance. Conclusions: This new study confirms that clinical efficacy of ISA101 vaccination is related to the strength of vaccine-induced HPV16-specific T-cell immunity and is an effective therapy for HPV16-induced high-grade VIN/VaIN. Clin Cancer Res; 22(10); 2342–50. ©2016 AACR. See related commentary by Karaki et al., p. 2317

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-2594

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 167

Metadata

Authors
van Poelgeest, M. I. E., Welters, M. J. P., Vermeij, R., Stynenbosch, L. F. M., Loof, N. M., Berends-van der Meer, D. M. A., Löwik, M. J. G., Hamming, I. L. E., van Esch, E. M. G., Hellebrekers, B. W. J., van Beurden, M., Schreuder, H. W., Kagie, M. J., Trimbos, J. B. M. Z., Fathers, L. M., Daemen, T., Hollema, H., Valentijn, A. R. P. M., Oostendorp, J., Oude Elberink, J. H. N. G., Fleuren, G. J., Bosse, T., Kenter, G. G., Stijnen, T., Nijman, H. W., Melief, C. J. M., & van der Burg, S. H.
Venue
Clinical Cancer Research
Published
2016-05-12
Volume
22
Issue
10
Pages
2342-2350
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2272228147
Cited by
167
References
1
FWCI
13.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2594
The paper
van Poelgeest, M. I. E., Welters, M. J. P., Vermeij, R., Stynenbosch, L. F. M., Loof, N. M., Berends-van der Meer, D. M. A., Löwik, M. J. G., Hamming, I. L. E., van Esch, E. M. G., Hellebrekers, B. W. J., van Beurden, M., Schreuder, H. W., Kagie, M. J., Trimbos, J. B. M. Z., Fathers, L. M., Daemen, T., Hollema, H., Valentijn, A. R. P. M., Oostendorp, J., . . . van der Burg, S. H. (2016). Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2594

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.